GLICLAZIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H21N3O3S
Molecular Weight	323.411
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2

InChI

InChIKey=BOVGTQGAOIONJV-BETUJISGSA-N

InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)/t12-,13+

HIDE SMILES / InChI

Molecular Formula	C15H21N3O3S
Molecular Weight	323.411
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.medicines.org.uk/emc/medicine/31089
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68005907 | https://www.drugs.com/cons/gliclazide.html

Gliclazide (BILXONA®) is an oral sulfonylurea hypoglycemic agent which is used in type 2 diabetes to stimulate insulin production. It differs from other related compounds by an N-containing heterocyclic ring with an endocyclic bond. Gliclazide (BILXONA®) reduces blood glucose levels by stimulating insulin secretion from the beta-cells of the islets of Langerhans. Increase in postprandial insulin and C-peptide secretion persists after two years of treatment. In addition to these metabolic properties, Gliclazide (BILXONA®) has haemovascular properties. It is not available for sale in the United States.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
potassium inwardly rectifying channel, subfamily J, member 11 1 Target ID: 16514.0 Gene Symbol: Kcnj11 Sources: https://www.drugbank.ca/drugs/DB01120	Inhibitor 8504		3.0 mM [Ki]
ATP-binding cassette sub-family C member 8 3 Target ID: CHEMBL1944490 Sources: https://www.drugbank.ca/drugs/DB01120	Inhibitor 8504		50.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: http://www.medicines.org.uk/emc/medicine/31089	Primary		Approved 8583	BILXONA Approved Use Non insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose. Launch Date 2015

C_max

Value	Dose	Analyte	Population
2.6 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=16	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.2 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=16	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.6 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.3 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.8 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.5 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.7 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
6.3 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
23.6 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
55.65 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
37.2 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
71.8 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
92.5 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
8.6 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=16	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.3 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=16	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.6 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.1 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.3 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.6 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.4 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.8 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
20.5 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
8% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.3% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=20		GLICLAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5% OTHER https://www.medicines.org.uk/emc/product/11631/smpc#PHARMACOKINETIC_PROPS		GLICLAZIDE plasma	Homo sapiens
5% OTHER GOV'T https://mhraproducts4853.blob.core.windows.net/docs/7357945bb5a0c49133c4ea64d51e2fb31ffe976d#page=15		GLICLAZIDE plasma	Homo sapiens

Doses

Dose	Population	Adverse events
2.1 g single, oral Overdose Dose: 2.1 g Route: oral Route: single Dose: 2.1 g Sources: https://pubmed.ncbi.nlm.nih.gov/26150642/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/26150642/	Disc. AE: Metabolic acidosis, Vomiting... AEs leading to discontinuation/dose reduction: Metabolic acidosis (grade 3-4) Vomiting Abdominal pain (grade 3) Hypoglycaemia Encephalopathy Acute kidney injury Haemodynamic instability (grade 3) Distributive shock (grade 3) Sources: https://pubmed.ncbi.nlm.nih.gov/26150642/
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11592575/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11592575/	Disc. AE: Hepatitis, Hemiplegia... AEs leading to discontinuation/dose reduction: Hepatitis Hemiplegia (grade 3) Dysphasia Lethargy Tonic-clonic convulsion Consciousness abnormal Stupor Sources: https://pubmed.ncbi.nlm.nih.gov/11592575/
198 mg 1 times / day multiple, oral Recommended Dose: 198 mg, 1 times / day Route: oral Route: multiple Dose: 198 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15787663/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/15787663/	Other AEs: Hypoglycaemia, Diarrhoea... Other AEs: Hypoglycaemia (10.1%) Diarrhoea (3.4%) Nausea (5.1%) Oedema (4.5%) Dizziness (6.5%) Headache (8.9%) Hypertension (3.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/15787663/

AEs

PubMed

Title	Date	PubMed
Phosphatidylinositol 3-kinase activation is required for sulfonylurea stimulation of glucose transport in rat skeletal muscle.	2004-02	14563700
Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis.	2003-11	14693302
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.	2003-11	14632720
Genetic cause of hyperglycaemia and response to treatment in diabetes.	2003-10-18	14575972
[Medication of the month. Gliclazide modified release (Uni Diamicron)].	2003-10	14677526
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.	2003-10	14614647
Monotherapy of type 2 diabetes with once-daily gliclazide modified release in primary care.	2003-10	14581160
Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.	2003-10	14534520
Reflex epilepsy and non-ketotic hyperglycemia.	2003-09	14684353
Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects.	2003-08	12939737
Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells.	2003-08	12939734
Pharmacokinetic and pharmacodynamic characterization of gliclazide in healthy volunteers.	2003-07	12934650
The application of the convective diffusion model and the film equilibrium model to surfactant-facilitated dissolution of gliclazide.	2003-07	12885387
Bioequivalence study of generic gliclazide and Diamicron formulations in healthy Thai male volunteers.	2003-07	12875349
Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.	2003-06	12909809
Diabetes and vascular disease: a new international trial.	2003-06	12878575
Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.	2003-06	12814458
Functional involvement of sulphonylurea receptor (SUR) type 1 and 2B in the activity of pig urethral ATP-sensitive K+ channels.	2003-06	12788825
Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells.	2003-05-19	12771929
Spectrofluorimetric and spectrophotometric determination of gliclazide in pharmaceuticals by derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole.	2003-05-02	12723907
Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.	2003-05	12803833
Study of the solubilization of gliclazide by aqueous micellar solutions.	2003-04	12661069
Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide.	2003-03-28	12646174
Monocyte matrix metalloproteinase production in Type 2 diabetes and controls--a cross sectional study.	2003-03-10	12672267
Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients.	2003-03-08	12623166
Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging.	2003-03-08	12623165
Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions.	2003-03-08	12623163
Effects of sulfonylureas on K(ATP) channel-dependent vasodilation.	2003-03-08	12623162
A simple and sensitive HPLC method for determination of gliclazide in human serum.	2003-03-05	12554153
Severe relapsing sulphonylurea-induced hypoglycaemia: a diagnostic and therapeutic challenge.	2003-02	12612336
Diabetes mellitus and weight control: differences of respiratory quotient in type 2 diabetic obese subjects receiving sulfonylureas and non-diabetic obese controls.	2003-02	12591550
Differential effects of sulphonylureas on the vasodilatory response evoked by K(ATP) channel openers.	2003-02	12588631
Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.	2003-02	12580986
Effects of inhibition of ATP-sensitive potassium channels on metabolic vasodilation in the human forearm.	2003-01	12519086
[A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].	2003	14570054
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.	2003	12725705
The mechanisms of inhibitory actions of gliclazide on neutrophils-endothelial cells adhesion and surface expression of endothelial adhesion molecules mediated by a high glucose concentration.	2002-12-31	12505752
Effect of ethanolic extract of Embelia ribes on dyslipidemia in diabetic rats.	2002-12-03	12458656
High-frequency insulin pulsatility and type 2 diabetes: from physiology and pathophysiology to clinical pharmacology.	2002-12	12703061
[Molecular mechanisms of insulin secretion].	2002-12	12703060
Hypoglycaemic activity of Alpinia galanga rhizome and its extracts in rabbits.	2002-12	12490221
Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.	2002-12	12489066
Gliclazide directly inhibits arginine-induced glucagon release.	2002-12	12475779
Interaction of the cytosolic domains of the Kir6.2 subunit of the K(ATP) channel is modulated by sulfonylureas.	2002-12	12475778
Sulfonylurea stimulation of insulin secretion.	2002-12	12475777
Effect of gliclazide on islet transplants.	2002-11	12431578
Remodelling of zero-stress state of small intestine in streptozotocin-induced diabetic rats. Effect of gliclazide.	2002-10	12469798
Gateways to Clinical Trials.	2002-09	12428432
Oral hypoglycaemic agent failure.	2002-07	12674170
[Effects of gliclazide on blood rheology of diabetes Wistar rat].	2001-06	12600119

Patents

Sample Use Guides

In Vivo Use Guide

The daily dose may vary from 1 to 4 tablets per day, i.e. from 30 to 120 mg taken orally in a single intake at breakfast time.

Route of Administration: Oral

In Vitro Use Guide

Gliclazide blocked whole-cell murine beta-cell Katp currents with an IC50 of 184 +/- 30 nmol/l (n = 6-10) but was much less effective in rat cardiac and smooth muscle (IC50s of 19.5 +/- 5.4 micromol/l (n = 6-12) and 37.9 +/- 1.0 micromol/l (n = 5-10), respectively). In all three tissues, the action of the drug on whole-cell Katp currents was rapidly reversible. In inside-out patches on beta-cells, gliclazide (1 micromol/l) produced a maximum of 66 +/- 13 % inhibition (n = 5), compared with more than 98 % block in the whole-cell configuration.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:40:52 GMT 2025` Edited by `admin` on `Mon Mar 31 19:40:52 GMT 2025`
Record UNII	G4PX8C4HKV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIAMICRON

Preferred Name

English

GLICLAZIDE

Official Name

English

SE 1702

Code

English

BENZENESULFONAMIDE, N-(((HEXAHYDROCYCLOPENTA(C)PYRROL-2(1H)-YL)AMINO)CARBONYL)-4-METHYL-

Systematic Name

English

SE-1702

Code

English

gliclazide [INN]

Common Name

English

GLICLAZIDE [MI]

Common Name

English

J3.151H

Code

English

Gliclazide [WHO-DD]

Common Name

English

S-1702

Code

English

NSC-758673

Code

English

GLICLAZIDE [EP MONOGRAPH]

Common Name

English

S-852

Code

English

GLICLAZIDE [JAN]

Common Name

English

1-(3-AZABICYCLO(3.3.0)OCT-3-YL)-3-(P-TOLYLSULFONYL)UREA

Common Name

English

GLIMICRON

Brand Name

English

GLICLAZIDE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C97936